Zobrazeno 1 - 10
of 31
pro vyhledávání: '"O N, Solopova"'
Autor:
E. N. Kosobokova, N. A. Kalinina, M. A. Baryshnikova, V. S. Pokrovsky, O. N. Solopova, T. A. Bogush, V. S. Kosorukov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 11 (2023)
Bioresource collection of the N. N. Blokhin National Medical Research Center of Oncology is a unique structured biobank that combines different types of primary and subsidiary samples and ensures its comprehensive characterization, including both gen
Externí odkaz:
https://doaj.org/article/547d69410aa346ac9f527cf336b72004
Autor:
L. A. Kesaeva, A. Yu. Bulanov, Yu. P. Finashutina, V. V. Tikhonova, O. N. Solopova, E. N. Misyurina, N. N. Kasatkina, N. A. Lyzhko, V. A. Misyurin, A. A. Turba, A. A. Solodovnik, I. N. Soldatova, A. V. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 6, Iss 2, Pp 48-54 (2019)
Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essentia
Externí odkaz:
https://doaj.org/article/ddc2d5ea07b847d58778f992b42fb958
Autor:
V. A. Misyurin, D. V. Kalenichenko, A. A. Rudakova, Yu. P. Finashutina, N. A. Lyzhko, V. V. Tikhonova, L. A. Kesaeva, O. N. Solopova, A. Е. Misyurina, A. N. Velikanov, M. А. Baryshnikovа, A. V. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 5, Iss 4, Pp 131-134 (2019)
Background. PRAME gene spontaneous expression is frequently observed in a cancer cell. The protein encoded by this gene increases the viability of tumour cell. NF-κB signalling pathway takes part in PRAME upregulation. It proposes, that stress condi
Externí odkaz:
https://doaj.org/article/87d06f320d814696885bc19a80580018
Autor:
A. A. Solodovnik, H. S. Mkrtchyan, V. A. Misyurin, V. V. Tikhonova, Yu. P. Finashutina, N. N. Kasatkina, O. N. Solopova, O. M. Votyakova, O. Yu. Yakimovich, O. M. Volodina, M. Yu. Kichigina, E. G. Medvedovskaya, A. S. Antipova, I. Z. Zavodnova, A. A. Semenova, G. R. Arakelyan, Yu. E. Ryabukhina, O. A. Kolomeytsev, A. D. Shirin, E. A. Osmanov, A. V. Misyurin
Publikováno v:
Успехи молекулярной онкологии, Vol 5, Iss 2, Pp 62-70 (2018)
Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and rel
Externí odkaz:
https://doaj.org/article/b0aa8abe11aa425e8a24ca45472d22ad
Autor:
M. V. Larina, Y. P. Finashutina, N. A. Lyzhko, V. A. Misyurin, V. N. Novoseletsky, D. A. Dolgikh, O. N. Solopova, A. M. Moysenovich, D. S. Balabashin, T. K. Aliev, A. V. Misyurin, M. P. Kirpichnikov
Publikováno v:
Russian Journal of Bioorganic Chemistry. 48:360-371
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7f1cef6ed9e6c6aa1d624a73548a231
https://doi.org/10.1134/s1068162022020133
https://doi.org/10.1134/s1068162022020133
Autor:
M. V. Larina, N. A. Lyzhko, L. A. Kesaeva, T. K. Aliev, NN Kasatkina, V. A. Misyurin, Mikhail P. Kirpichnikov, A. V. Misyurin, O. N. Solopova, A. A. Turba, Yu. P. Finashutina
Publikováno v:
Doklady Biochemistry and Biophysics. 498:199-202
Two monoclonal antibodies recognizing non-overlapping epitopes of the PRAME protein were injected into immunocompetent mice to study their influence on the growth of subcutaneous tumor nodes. The B16F10 murine melanoma line, either expressing human P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cf122ed562a8a5d3569ab71e94a96a6
https://doi.org/10.1134/s1607672921030091
https://doi.org/10.1134/s1607672921030091
Autor:
D. S. Balabashin, D. A. Dolgikh, A. A. Panina, P. G. Sveshnikov, N. V. Novoseletsky, S. A. Yakimov, V. S. Rybchenko, T. K. Aliev, O. N. Solopova, Mikhail P. Kirpichnikov
Publikováno v:
Russian Journal of Bioorganic Chemistry. 46:778-786
Humanization of antibodies for the development of novel therapeutic agents with low immunogenicity remains a topical problem in modern science. In the present work we describe the humanization of murine antibody B16 which binds and neutralizes human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bcc68827f249905714b3ba2182b7c5a
https://doi.org/10.1134/s1068162020050209
https://doi.org/10.1134/s1068162020050209
Autor:
A. A. Panina, V. S. Rybchenko, O. N. Solopova, D. S. Balabashin, S. A. Yakimov, T. K. Aliev, D. A. Dolgikh, P. G. Sveshnikov, M. P. Kirpichnikov
Publikováno v:
Acta Naturae. 12:95-104
The development of and research into new therapies that can selectively and effectively destroy tumor cells that overexpress the ErbB2 receptor is apressing task. Recently, research into the use of type I interferons in the treatment of cancer has in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a73be408728343d2a7b8738579d3270a
https://doi.org/10.32607/actanaturae.11156
https://doi.org/10.32607/actanaturae.11156
Autor:
D. S. Balabashin, V. A. Toporova, P. G. Sveshnikov, T. K. Aliev, A. A. Panina, Mikhail P. Kirpichnikov, V. V. Argentova, O. N. Solopova, V. S. Rybchenko, D. A. Dolgikh, S. A. Yakimov
Publikováno v:
Russian Journal of Bioorganic Chemistry. 46:572-581
The development of new therapies for malignant tumors is an urgent task. Currently, the humanized antibody trastuzumab is considered the “gold standard” in the complex treatment of breast tumors with overexpression of HER2, human epidermal growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e28ceefcc0b9f462a2bfb183be475c5e
https://doi.org/10.1134/s1068162020040159
https://doi.org/10.1134/s1068162020040159
Autor:
A. V. Misyurin, A. Yu. Bulanov, I. N. Soldatova, V. V. Tikhonova, E. N. Misyurina, O. N. Solopova, N. A. Lyzhko, A. A. Turba, NN Kasatkina, V. A. Misyurin, A. A. Solodovnik, Yu. P. Finashutina, L. A. Kesaeva
Publikováno v:
Uspehi Molekulârnoj Onkologii, Vol 6, Iss 2, Pp 48-54 (2019)
Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f267ea2787106b79be8803d29dcd7d02
https://doi.org/10.17650/2313-805x-2019-6-2-48-54
https://doi.org/10.17650/2313-805x-2019-6-2-48-54